Literature DB >> 1633861

The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow.

C J Porter1, S M Moghimi, L Illum, S S Davis.   

Abstract

Small colloidal particulates (150 nm and below, in diameter) can be redirected specifically to the rabbit bone marrow following intravenous administration by coating their surface with the block co-polymer poloxamer-407, a non-ionic surfactant. The coated colloids are sequestered by the sinusoidal endothelial cells of the bone marrow and are accumulated in dense bodies within these cells. The uptake of poloxamer-407-coated colloids by marrow endothelial cells suggests that the steric repulsive barrier, imposed by the polyoxyethylene segment of the polymer, to particle-cell interaction can apparently be overcome by a specific interaction mechanism(s) with the cell surface. Such a dramatic uptake cannot be achieved with other block co-polymers of similar structure to poloxamer-407. The application of the current model for the site-specific targeting of drug carriers to bone marrow and the prevention of the adherence of metastases of tumours which selectively colonize the bone marrow endothelium is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633861     DOI: 10.1016/0014-5793(92)80655-z

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

Review 1.  Bone marrow-targeted liposomal carriers.

Authors:  Keitaro Sou; Beth Goins; Babatunde O Oyajobi; Bruno L Travi; William T Phillips
Journal:  Expert Opin Drug Deliv       Date:  2011-01-31       Impact factor: 6.648

Review 2.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

Review 3.  A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

Authors:  Gilles Dumortier; Jean Louis Grossiord; Florence Agnely; Jean Claude Chaumeil
Journal:  Pharm Res       Date:  2006-11-11       Impact factor: 4.200

4.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.

Authors:  Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Josephine Sung; Gaurav Luther; Frank X Gu; Etgar Levy-Nissenbaum; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad
Journal:  Biomaterials       Date:  2006-10-20       Impact factor: 12.479

Review 5.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

Review 6.  Advances in Controlled Drug Delivery for Treatment of Osteoporosis.

Authors:  T A Asafo-Adjei; A J Chen; A Najarzadeh; D A Puleo
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 7.  Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles.

Authors:  Randall Toy; Pubudu M Peiris; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Nanomedicine (Lond)       Date:  2014-01       Impact factor: 5.307

8.  Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients.

Authors:  Katayoun Derakhshandeh; Marzieh Soheili; Simin Dadashzadeh; Reza Saghiri
Journal:  Int J Nanomedicine       Date:  2010-08-09

9.  Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers.

Authors:  S Stolnik; S E Dunn; M C Garnett; M C Davies; A G Coombes; D C Taylor; M P Irving; S C Purkiss; T F Tadros; S S Davis
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.